{
    "hands_on_practices": [
        {
            "introduction": "Diagnosing complex conditions like tuberculous meningitis is rarely a matter of a single definitive test; instead, it involves a careful synthesis of evidence. This exercise will guide you through a quantitative approach to clinical diagnosis, demonstrating how to systematically combine clinical signs and laboratory results. By first calculating a pretest probability from a clinical scoring system and then updating this probability using likelihood ratios from cerebrospinal fluid analysis, you will practice applying Bayes' theorem—a cornerstone of evidence-based medicine .",
            "id": "4463037",
            "problem": "A patient with central nervous system symptoms suggestive of meningitis is evaluated using a clinically derived risk score for tuberculous meningitis. Consider a 35-year-old individual with subacute meningitic symptoms for 3 weeks, a right abducens nerve palsy consistent with a cranial neuropathy, and serum sodium of $128 \\text{ mmol/L}$ consistent with hyponatremia. A clinical scoring system assigns the following weights: duration greater than two weeks ($w_{\\text{dur}} = 2.0$), cranial neuropathy ($w_{\\text{cran}} = 3.0$), and hyponatremia ($w_{\\text{hypo}} = 1.5$). The total score is defined by $S = w_{\\text{dur}} \\, X_{\\text{dur}} + w_{\\text{cran}} \\, X_{\\text{cran}} + w_{\\text{hypo}} \\, X_{\\text{hypo}}$, where each $X$ is an indicator variable that equals $1$ if the feature is present and $0$ otherwise. The score is calibrated to the pretest probability via the log-odds relation $\\ell = \\alpha + \\gamma S$, with calibration constants $\\alpha = -2.2$ and $\\gamma = 0.35$, and pretest probability given by the logistic transformation of the log-odds. Cerebrospinal fluid (CSF) analysis reveals findings commonly associated with tuberculous meningitis. Using the foundational relation of Bayes’ theorem for diagnostic updates in odds form, the following cerebrospinal fluid likelihood ratios (LR) for positive findings are provided: elevated CSF adenosine deaminase (ADA) above $10$ $\\text{U}/\\text{L}$ has $\\text{LR}^{+} = 6.0$, lymphocyte fraction greater than $70\\%$ has $\\text{LR}^{+} = 2.8$, CSF protein greater than $1.0$ $\\text{g}/\\text{L}$ has $\\text{LR}^{+} = 2.2$, and CSF-to-blood glucose ratio less than $0.4$ has $\\text{LR}^{+} = 2.5$. Assume all four findings are present and conditionally independent given disease status. Starting from the core definitions of probability, odds, and Bayes’ theorem, compute the patient’s posterior probability of tuberculous meningitis after incorporating all cerebrospinal fluid findings. Round your final posterior probability to four significant figures and express it as a decimal without a percentage sign.",
            "solution": "The problem requires the calculation of the posterior probability of tuberculous meningitis (TBM) for a patient, starting from a pretest probability derived from a clinical scoring system and updating it with findings from a cerebrospinal fluid (CSF) analysis using Bayes' theorem.\n\nFirst, we establish the fundamental definitions. The odds, $O$, of an event with probability $P$ are defined as the ratio of the probability that the event occurs to the probability that it does not occur:\n$$O = \\frac{P}{1-P}$$\nConversely, the probability can be determined from the odds using the relation:\n$$P = \\frac{O}{1+O}$$\nThe log-odds, $\\ell$, is the natural logarithm of the odds: $\\ell = \\ln(O)$.\n\nThe first step is to calculate the pretest probability of TBM based on the patient's clinical presentation. The problem provides a scoring system where the total score, $S$, is a weighted sum of indicator variables for specific clinical features. The formula is:\n$$S = w_{\\text{dur}} \\, X_{\\text{dur}} + w_{\\text{cran}} \\, X_{\\text{cran}} + w_{\\text{hypo}} \\, X_{\\text{hypo}}$$\nThe indicator variable $X_i$ is $1$ if the feature is present and $0$ otherwise. The weights are given as $w_{\\text{dur}} = 2.0$, $w_{\\text{cran}} = 3.0$, and $w_{\\text{hypo}} = 1.5$.\n\nBased on the patient's data:\n- Symptom duration is $3$ weeks, which is greater than two weeks, so $X_{\\text{dur}} = 1$.\n- The patient has an abducens nerve palsy, a form of cranial neuropathy, so $X_{\\text{cran}} = 1$.\n- Serum sodium is $128$ $\\text{mmol}/\\text{L}$, which is consistent with hyponatremia, so $X_{\\text{hypo}} = 1$.\n\nSubstituting these values into the score equation:\n$$S = (2.0)(1) + (3.0)(1) + (1.5)(1) = 2.0 + 3.0 + 1.5 = 6.5$$\n\nNext, we calculate the pretest log-odds, $\\ell_{\\text{pre}}$, using the provided calibration formula $\\ell = \\alpha + \\gamma S$. The constants are given as $\\alpha = -2.2$ and $\\gamma = 0.35$.\n$$\\ell_{\\text{pre}} = -2.2 + (0.35)(6.5)$$\n$$\\ell_{\\text{pre}} = -2.2 + 2.275 = 0.075$$\n\nFrom the log-odds, we find the pretest odds, $O_{\\text{pre}}$:\n$$O_{\\text{pre}} = \\exp(\\ell_{\\text{pre}}) = \\exp(0.075)$$\n\nNow we incorporate the CSF findings using Bayes' theorem in odds form. This form states that the posterior odds are the product of the pretest odds and the likelihood ratio (LR) of the evidence:\n$$O_{\\text{post}} = O_{\\text{pre}} \\times \\text{LR}_{\\text{evidence}}$$\nThe evidence consists of four CSF findings, all of which are present. The problem provides the positive likelihood ratios ($\\text{LR}^{+}$) for each finding:\n- Elevated ADA ($\\text{LR}_{1}^{+}$): $6.0$\n- High lymphocyte fraction ($\\text{LR}_{2}^{+}$): $2.8$\n- High CSF protein ($\\text{LR}_{3}^{+}$): $2.2$\n- Low CSF/blood glucose ratio ($\\text{LR}_{4}^{+}$): $2.5$\n\nThe problem states that these findings are conditionally independent given the disease status. Therefore, the total likelihood ratio for the combined evidence is the product of the individual likelihood ratios:\n$$\\text{LR}_{\\text{total}} = \\text{LR}_{1}^{+} \\times \\text{LR}_{2}^{+} \\times \\text{LR}_{3}^{+} \\times \\text{LR}_{4}^{+}$$\n$$\\text{LR}_{\\text{total}} = 6.0 \\times 2.8 \\times 2.2 \\times 2.5$$\n$$\\text{LR}_{\\text{total}} = (6.0 \\times 2.5) \\times (2.8 \\times 2.2) = 15.0 \\times 6.16 = 92.4$$\n\nWe can now calculate the posterior odds, $O_{\\text{post}}$:\n$$O_{\\text{post}} = O_{\\text{pre}} \\times \\text{LR}_{\\text{total}} = \\exp(0.075) \\times 92.4$$\n\nFinally, we convert the posterior odds back to a posterior probability, $P_{\\text{post}}$, using the formula $P = O/(1+O)$:\n$$P_{\\text{post}} = \\frac{O_{\\text{post}}}{1 + O_{\\text{post}}} = \\frac{92.4 \\exp(0.075)}{1 + 92.4 \\exp(0.075)}$$\n\nTo obtain the numerical value, we first evaluate the exponential term:\n$$\\exp(0.075) \\approx 1.077884$$\nNow we compute the posterior odds:\n$$O_{\\text{post}} \\approx 92.4 \\times 1.077884 \\approx 99.606495$$\nAnd the posterior probability:\n$$P_{\\text{post}} \\approx \\frac{99.606495}{1 + 99.606495} = \\frac{99.606495}{100.606495} \\approx 0.9900604$$\n\nThe problem requires rounding the final answer to four significant figures.\n$$P_{\\text{post}} \\approx 0.9901$$",
            "answer": "$$\\boxed{0.9901}$$"
        },
        {
            "introduction": "Hyponatremia is a common and potentially life-threatening complication in patients with tuberculous meningitis, requiring precise diagnosis and management. This practice presents a clinical scenario that challenges you to differentiate between the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and cerebral salt wasting (CSW), two key causes of hyponatremia in this setting. Successfully navigating this problem requires you to integrate your understanding of fluid-electrolyte physiology with the specific hemodynamic and therapeutic priorities of a patient with active CNS inflammation .",
            "id": "4463016",
            "problem": "A hospitalized adult with confirmed tuberculous meningitis (TBM) presents on hospital day $5$ with worsening headache, new lethargy, and one brief focal seizure. He has been receiving first-line antituberculous therapy and dexamethasone. On examination he is afebrile, alert but slowed, without orthostatic changes, jugular venous distension, edema, or mucosal dryness; capillary refill is normal and body weight is unchanged from admission. Laboratory data show serum sodium $122$ mmol/L, potassium $3.9$ mmol/L, glucose $90$ mg/dL, blood urea nitrogen $6$ mg/dL, creatinine $0.7$ mg/dL, measured serum osmolality $252$ mOsm/kg, triglycerides $110$ mg/dL, thyroid-stimulating hormone $2.1$ mIU/L, and $8$ AM serum cortisol $18$ mcg/dL. Urine osmolality is $560$ mOsm/kg with urine sodium $62$ mmol/L. There is no history of diuretic use. Consider the regulation of water balance by Antidiuretic Hormone (ADH), the classification of hyponatremia by tonicity, and renal handling of sodium and water under central nervous system inflammation.\n\nBased on first principles, determine whether the pattern is most consistent with Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) or an alternative diagnosis. Then, select the single best next step that integrates appropriate immediate management of hyponatremia while accounting for pathophysiologic priorities specific to TBM, including cerebral perfusion and ongoing anti-tubercular therapy. Choose one:\n\nA. Diagnose SIADH and institute strict fluid restriction to less than $500$ mL/day; discontinue dexamethasone and avoid hypertonic saline to prevent overly rapid correction.\n\nB. Diagnose cerebral salt wasting and begin large-volume isotonic saline resuscitation with fludrocortisone to correct sodium and intravascular depletion.\n\nC. Diagnose SIADH; continue dexamethasone and antituberculous therapy; avoid hypotonic fluids; for symptomatic or severe hyponatremia initiate $3\\%$ hypertonic saline with a target rise in serum sodium no greater than $8$ to $10$ mmol/L in $24$ hours, then employ cautious fluid restriction (for example, $800$ to $1000$ mL/day) with oral salt supplementation and consideration of a loop diuretic, explicitly maintaining euvolemia to preserve cerebral perfusion in TBM.\n\nD. Diagnose primary polydipsia; treat with water restriction alone and avoid saline solutions to reduce the risk of osmotic demyelination.\n\nE. Diagnose SIADH and initiate a vasopressin receptor antagonist (tolvaptan) as first-line therapy, anticipating augmented efficacy during rifampin-containing antituberculous therapy.",
            "solution": "The user has provided a clinical problem for validation and solution.\n\n### Step 1: Extract Givens\n\n- **Diagnosis**: Confirmed tuberculous meningitis (TBM) in a hospitalized adult.\n- **Timeline**: Hospital day $5$.\n- **Clinical Presentation**: Worsening headache, new lethargy, one brief focal seizure.\n- **Current Medications**: First-line antituberculous therapy and dexamethasone.\n- **Physical Examination**: Afebrile, alert but slowed. No orthostatic changes, no jugular venous distension, no edema, no mucosal dryness. Capillary refill is normal. Body weight is unchanged from admission.\n- **Laboratory Data**:\n  - Serum sodium: $122$ mmol/L\n  - Serum potassium: $3.9$ mmol/L\n  - Serum glucose: $90$ mg/dL\n  - Blood urea nitrogen (BUN): $6$ mg/dL\n  - Serum creatinine: $0.7$ mg/dL\n  - Measured serum osmolality: $252$ mOsm/kg\n  - Triglycerides: $110$ mg/dL\n  - Thyroid-stimulating hormone (TSH): $2.1$ mIU/L\n  - $8$ AM serum cortisol: $18$ mcg/dL\n  - Urine osmolality: $560$ mOsm/kg\n  - Urine sodium: $62$ mmol/L\n- **History**: No diuretic use.\n- **Task**: Determine the most likely diagnosis (SIADH vs. alternative) and select the single best next step in management.\n\n### Step 2: Validate Using Extracted Givens\n\n1.  **Scientific Groundedness**: The problem describes a realistic and well-documented clinical scenario. Hyponatremia is a common and serious complication of TBM, and the differential diagnosis between Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) and Cerebral Salt Wasting (CSW) is a classic challenge in neurocritical care. The physiological principles of water balance, ADH action, and renal function are central to the problem. All data and concepts are based on established medical science.\n2.  **Well-Posedness**: The problem provides sufficient clinical and laboratory data to arrive at a reasoned diagnosis and management plan. Key information for differentiating SIADH from CSW (clinical volume status) and for ruling out other causes of hyponatremia is provided.\n3.  **Objectivity**: The language is objective and clinical, presenting facts without bias.\n4.  **Consistency Check**:\n    - The hyponatremia (serum sodium $122$ mmol/L) is hypotonic, as confirmed by the low measured serum osmolality ($252$ mOsm/kg, which is less than the normal range of $275-295$ mOsm/kg).\n    - We can calculate the expected serum osmolality to check for an osmolar gap:\n      $$ \\text{Calculated Osmolality} \\approx 2 \\times [\\text{Na}^+] + \\frac{[\\text{Glucose}]}{18} + \\frac{[\\text{BUN}]}{2.8} $$\n      $$ \\text{Calculated Osmolality} \\approx 2 \\times 122 + \\frac{90}{18} + \\frac{6}{2.8} \\approx 244 + 5 + 2.14 \\approx 251.14 \\text{ mOsm/kg} $$\n      This calculated value is very close to the measured value of $252$ mOsm/kg, indicating no significant osmolar gap. The normal triglyceride level rules out pseudohyponatremia, and the normal glucose rules out hypertonic hyponatremia.\n    - The data is internally consistent and complete for the task. Other potential causes of hyponatremia are appropriately excluded by the provided data: normal renal function (BUN, creatinine), normal thyroid function (TSH), and adequate adrenal function (cortisol).\n\n### Step 3: Verdict and Action\n\nThe problem statement is **valid**. It is a well-formed, scientifically sound, and objective clinical problem that can be solved using first principles of physiology and medicine.\n\n### Solution Derivation\n\nThe primary task is to diagnose the cause of the hypotonic hyponatremia and select the best management strategy.\n\n1.  **Diagnosis**: The differential diagnosis for hypotonic hyponatremia with inappropriately concentrated urine (urine osmolality $>100$ mOsm/kg) in a patient with a CNS disorder primarily lies between SIADH and CSW.\n    - **Urine studies**: The urine is inappropriately concentrated (Urine Osmolality $560$ mOsm/kg) relative to the serum (Serum Osmolality $252$ mOsm/kg), and the urine sodium is elevated ($62$ mmol/L). These findings are consistent with *both* SIADH and CSW. In SIADH, high urine sodium is due to natriuresis from volume expansion. In CSW, it is due to a primary renal salt leak. Therefore, urine studies alone are not sufficient to differentiate.\n    - **Volume Status**: The key differentiator is the patient's extracellular fluid (ECF) volume status.\n      - **SIADH** is a state of water retention, leading to euvolemia or mild hypervolemia.\n      - **CSW** is a state of primary salt loss, leading to volume depletion (hypovolemia).\n    - **Clinical Assessment**: The physical examination findings are definitive in this case. The patient has \"no orthostatic changes,\" \"body weight is unchanged from admission,\" and there are no signs of dehydration (\"no mucosal dryness,\" \"normal capillary refill\") or fluid overload (\"no jugular venous distension, no edema\"). This clinical picture is the definition of **euvolemia**.\n    - **Conclusion**: The combination of hypotonic hyponatremia, euvolemia, and inappropriately concentrated urine with high urine sodium establishes the diagnosis of **SIADH**. The diagnosis of CSW is excluded by the clear evidence of euvolemia. Primary polydipsia is excluded by the high urine osmolality.\n\n2.  **Management Strategy**: The patient is experiencing severe, symptomatic hyponatremia (new lethargy and a seizure with a serum sodium of $122$ mmol/L). This constitutes a neurological emergency.\n    - **Immediate Treatment**: The standard of care for acute, symptomatic hyponatremia is the administration of **$3\\%$ hypertonic saline**. The goal is to raise the serum sodium level promptly to alleviate acute cerebral edema and stop symptoms, but in a controlled manner to avoid osmotic demyelination syndrome (ODS). A typical target is an initial rise of $4-6$ mmol/L over several hours, with a total correction not exceeding $8-10$ mmol/L in the first $24$ hours.\n    - **Therapy for TBM**: The underlying disease, TBM, must continue to be treated aggressively. This includes continuing **antituberculous therapy** and **dexamethasone**. Dexamethasone is crucial for reducing the inflammatory response in the CNS, which mitigates complications like vasculitis and hydrocephalus. Discontinuing it would be harmful.\n    - **Fluid Management Considerations**: In TBM, maintaining adequate cerebral perfusion pressure (CPP) is critical to prevent ischemic injury from vasculitis. Therefore, creating a state of hypovolemia through overly aggressive fluid restriction is dangerous. Management should aim to maintain euvolemia. Avoiding hypotonic fluids (like D5W or $0.45\\%$ saline) is essential as they would worsen the hyponatremia in SIADH.\n    - **Long-term Management**: After the acute emergency is resolved with hypertonic saline, further management of SIADH includes cautious fluid restriction (e.g., $800-1000$ mL/day), increased oral salt intake (salt tablets), and potentially loop diuretics like furosemide (which promote excretion of water in excess of salt).\n\n### Option-by-Option Analysis\n\n**A. Diagnose SIADH and institute strict fluid restriction to less than $500$ mL/day; discontinue dexamethasone and avoid hypertonic saline to prevent overly rapid correction.**\n- **Analysis**: While the diagnosis of SIADH is correct, the management is flawed. The patient is symptomatic and requires urgent correction with hypertonic saline, not its avoidance. Strict fluid restriction to $<500$ mL/day is dangerous as it risks hypovolemia and reduced cerebral perfusion in a TBM patient. Discontinuing dexamethasone is contraindicated.\n- **Verdict**: **Incorrect**.\n\n**B. Diagnose cerebral salt wasting and begin large-volume isotonic saline resuscitation with fludrocortisone to correct sodium and intravascular depletion.**\n- **Analysis**: The diagnosis of CSW is incorrect. The patient is clinically euvolemic. Treating a euvolemic SIADH patient with large volumes of isotonic saline will worsen the hyponatremia, as the kidneys will excrete the sodium but retain the free water under the influence of ADH.\n- **Verdict**: **Incorrect**.\n\n**C. Diagnose SIADH; continue dexamethasone and antituberculous therapy; avoid hypotonic fluids; for symptomatic or severe hyponatremia initiate $3\\%$ hypertonic saline with a target rise in serum sodium no greater than $8$ to $10$ mmol/L in $24$ hours, then employ cautious fluid restriction (for example, $800$ to $1000$ mL/day) with oral salt supplementation and consideration of a loop diuretic, explicitly maintaining euvolemia to preserve cerebral perfusion in TBM.**\n- **Analysis**: This option correctly identifies the diagnosis as SIADH. The management plan is comprehensive and aligns perfectly with best practices. It correctly calls for continuing essential TBM therapies, using hypertonic saline for symptomatic hyponatremia with appropriate safety limits, and employing a cautious long-term strategy. Most importantly, it correctly emphasizes the need to maintain euvolemia to preserve cerebral perfusion, which is a critical consideration specific to TBM.\n- **Verdict**: **Correct**.\n\n**D. Diagnose primary polydipsia; treat with water restriction alone and avoid saline solutions to reduce the risk of osmotic demyelination.**\n- **Analysis**: The diagnosis of primary polydipsia is incorrect. The high urine osmolality ($560$ mOsm/kg) rules out this condition, in which urine should be maximally dilute ($<100$ mOsm/kg).\n- **Verdict**: **Incorrect**.\n\n**E. Diagnose SIADH and initiate a vasopressin receptor antagonist (tolvaptan) as first-line therapy, anticipating augmented efficacy during rifampin-containing antituberculous therapy.**\n- **Analysis**: The diagnosis of SIADH is correct. However, vaptans are not first-line for acute symptomatic hyponatremia; hypertonic saline is. More importantly, the statement about drug interaction is factually wrong. Rifampin is a first-line antituberculous drug and a potent inducer of the CYP3A4 enzyme system. Tolvaptan is metabolized by CYP3A4. Therefore, concurrent use of rifampin would *decrease* the concentration and efficacy of tolvaptan, not augment it. This makes the recommendation both clinically suboptimal and pharmacologically incorrect.\n- **Verdict**: **Incorrect**.",
            "answer": "$$\\boxed{C}$$"
        },
        {
            "introduction": "The pharmacological management of tuberculous meningitis is a delicate balancing act, requiring potent multidrug therapy while navigating the risk of significant side effects. This exercise provides a practical application of clinical pharmacology, focusing on the essential skill of tailoring an antitubercular regimen for a patient with pre-existing organ dysfunction. You will perform weight-based dose calculations and apply specific adjustments for hepatic impairment, thereby quantifying the trade-offs between achieving therapeutic drug exposure in the CNS and mitigating the risk of hepatotoxicity .",
            "id": "4462964",
            "problem": "A 60-year-old adult with Central Nervous System (CNS) tuberculous meningitis (TBM) requires induction therapy with first-line antitubercular agents. For TBM, accepted weight-based target doses are isoniazid $10 \\,\\text{mg/kg}$, rifampicin $10 \\,\\text{mg/kg}$, pyrazinamide $25 \\,\\text{mg/kg}$, and ethambutol $20 \\,\\text{mg/kg}$. The patient has Child-Pugh class B hepatic dysfunction. To mitigate hepatotoxicity under moderate hepatic dysfunction, you will apply the following adjustment policy: reduce isoniazid by $0.30$ (that is, thirty percent), reduce rifampicin by $0.20$ (that is, twenty percent), omit pyrazinamide entirely, and leave ethambutol unchanged. Assume linear scaling of dose by body mass, that is, daily dose $D$ equals dose-per-kilogram $d$ multiplied by body mass $m$, and assume that the daily quantity of drug undergoing hepatic metabolism is approximated by $D \\times f_{\\text{hep}}$, where $f_{\\text{hep}}$ is the hepatic metabolism fraction of the administered dose. Use the following hepatic metabolism fractions: $f_{\\text{hep},\\text{isoniazid}} = 0.90$, $f_{\\text{hep},\\text{rifampicin}} = 0.70$, $f_{\\text{hep},\\text{pyrazinamide}} = 0.95$, and $f_{\\text{hep},\\text{ethambutol}} = 0.20$. The patient’s body mass is $60 \\,\\text{kg}$.\n\nStarting from the principles of weight-based dosing and hepatic metabolic handling, derive the adjusted daily doses and compute the total adjusted daily quantity of drug undergoing hepatic metabolism (the sum across the four drugs after adjustments). Express the final quantity in $\\text{mg/day}$. In your derivation, explain the pharmacological consequences of these adjustments for CNS drug exposure and toxicity risk. The final answer must be a single real-valued number.",
            "solution": "The problem statement has been validated and is deemed scientifically grounded, well-posed, and objective. It provides all necessary data and definitions for a unique, meaningful solution based on established pharmacological principles.\n\nThe central task is to calculate the total daily quantity of administered antitubercular drugs that undergo hepatic metabolism in a patient with moderate hepatic dysfunction, after applying specified dose adjustments. The foundation of this calculation rests on the principles of weight-based dosing and fractional metabolic clearance.\n\nLet $m$ be the patient's body mass, given as $m = 60 \\, \\text{kg}$.\nLet $d_{\\text{std,drug}}$ be the standard dose per kilogram for a given drug.\nLet $D_{\\text{std,drug}}$ be the standard total daily dose, calculated as $D_{\\text{std,drug}} = d_{\\text{std,drug}} \\times m$.\nLet $D_{\\text{adj,drug}}$ be the adjusted total daily dose, reflecting modifications for hepatic dysfunction.\nLet $f_{\\text{hep,drug}}$ be the fraction of the administered dose of a drug that is metabolized by the liver.\nLet $M_{\\text{hep,drug}}$ be the quantity of the adjusted dose metabolized by the liver per day, approximated by the formula $M_{\\text{hep,drug}} = D_{\\text{adj,drug}} \\times f_{\\text{hep,drug}}$.\nThe total daily quantity of drug undergoing hepatic metabolism, $M_{\\text{hep,total}}$, is the sum of the individual quantities for each drug in the regimen:\n$$M_{\\text{hep,total}} = \\sum_{\\text{drug}} M_{\\text{hep,drug}}$$\n\nWe will now compute the adjusted dose and corresponding hepatic metabolic load for each of the four drugs.\n\n1.  **Isoniazid (INH):**\n    The standard dose-per-kilogram is $d_{\\text{std,INH}} = 10 \\, \\text{mg/kg}$.\n    The standard daily dose is $D_{\\text{std,INH}} = 10 \\, \\text{mg/kg} \\times 60 \\, \\text{kg} = 600 \\, \\text{mg}$.\n    The dose is to be reduced by $0.30$ (i.e., $30\\%$). The adjustment factor is $(1 - 0.30) = 0.70$.\n    The adjusted daily dose is $D_{\\text{adj,INH}} = 600 \\, \\text{mg} \\times 0.70 = 420 \\, \\text{mg}$.\n    The hepatic metabolism fraction is $f_{\\text{hep,INH}} = 0.90$.\n    The quantity of isoniazid undergoing hepatic metabolism is:\n    $$M_{\\text{hep,INH}} = D_{\\text{adj,INH}} \\times f_{\\text{hep,INH}} = 420 \\, \\text{mg} \\times 0.90 = 378 \\, \\text{mg/day}$$\n\n2.  **Rifampicin (RIF):**\n    The standard dose-per-kilogram is $d_{\\text{std,RIF}} = 10 \\, \\text{mg/kg}$.\n    The standard daily dose is $D_{\\text{std,RIF}} = 10 \\, \\text{mg/kg} \\times 60 \\, \\text{kg} = 600 \\, \\text{mg}$.\n    The dose is to be reduced by $0.20$ (i.e., $20\\%$). The adjustment factor is $(1 - 0.20) = 0.80$.\n    The adjusted daily dose is $D_{\\text{adj,RIF}} = 600 \\, \\text{mg} \\times 0.80 = 480 \\, \\text{mg}$.\n    The hepatic metabolism fraction is $f_{\\text{hep,RIF}} = 0.70$.\n    The quantity of rifampicin undergoing hepatic metabolism is:\n    $$M_{\\text{hep,RIF}} = D_{\\text{adj,RIF}} \\times f_{\\text{hep,RIF}} = 480 \\, \\text{mg} \\times 0.70 = 336 \\, \\text{mg/day}$$\n\n3.  **Pyrazinamide (PZA):**\n    The adjustment policy dictates that pyrazinamide be omitted entirely.\n    Therefore, the adjusted daily dose is $D_{\\text{adj,PZA}} = 0 \\, \\text{mg}$.\n    The quantity of pyrazinamide undergoing hepatic metabolism is consequently zero:\n    $$M_{\\text{hep,PZA}} = 0 \\, \\text{mg/day}$$\n\n4.  **Ethambutol (EMB):**\n    The standard dose-per-kilogram is $d_{\\text{std,EMB}} = 20 \\, \\text{mg/kg}$.\n    The standard daily dose is $D_{\\text{std,EMB}} = 20 \\, \\text{mg/kg} \\times 60 \\, \\text{kg} = 1200 \\, \\text{mg}$.\n    The dose is to remain unchanged.\n    The adjusted daily dose is $D_{\\text{adj,EMB}} = 1200 \\, \\text{mg}$.\n    The hepatic metabolism fraction is $f_{\\text{hep,EMB}} = 0.20$.\n    The quantity of ethambutol undergoing hepatic metabolism is:\n    $$M_{\\text{hep,EMB}} = D_{\\text{adj,EMB}} \\times f_{\\text{hep,EMB}} = 1200 \\, \\text{mg} \\times 0.20 = 240 \\, \\text{mg/day}$$\n\nNow, we sum the individual hepatic metabolic loads to find the total:\n$$M_{\\text{hep,total}} = M_{\\text{hep,INH}} + M_{\\text{hep,RIF}} + M_{\\text{hep,PZA}} + M_{\\text{hep,EMB}}$$\n$$M_{\\text{hep,total}} = 378 \\, \\text{mg/day} + 336 \\, \\text{mg/day} + 0 \\, \\text{mg/day} + 240 \\, \\text{mg/day}$$\n$$M_{\\text{hep,total}} = 954 \\, \\text{mg/day}$$\n\nPharmacological Consequences of Dose Adjustments:\nThe purpose of these dose adjustments is to mitigate the risk of drug-induced liver injury (DILI) in a patient with compromised hepatic function (Child-Pugh Class B). The first-line antitubercular regimen is notoriously hepatotoxic, with the relative risk being pyrazinamide > isoniazid > rifampicin.\n-   **Omission of Pyrazinamide (PZA):** This is the most critical adjustment for hepatoprotection. PZA is the most hepatotoxic of the first-line agents, and its omission drastically reduces the overall risk of DILI. However, PZA has potent sterilizing activity, particularly in the acidic environment of caseous granulomas. Its absence removes a key component of the early bactericidal effect of the regimen, which often necessitates extending the total duration of therapy to ensure microbiological cure and prevent relapse.\n-   **Reduction of Isoniazid (INH) and Rifampicin (RIF):** Both INH and RIF are extensively metabolized by the liver ($f_{\\text{hep,INH}}=0.90$, $f_{\\text{hep,RIF}}=0.70$) and can cause hepatotoxicity. Reducing their doses (by $30\\%$ and $20\\%$, respectively) decreases the metabolic burden on the already impaired liver. A primary concern with this adjustment is the potential for reduced therapeutic efficacy. Tuberculous meningitis requires excellent drug penetration into the cerebrospinal fluid (CSF) and brain parenchyma. Lowering the systemic dose of these two cornerstone drugs might result in sub-therapeutic concentrations at the site of infection, risking treatment failure or the emergence of drug resistance. This represents a critical trade-off between toxicity avoidance and bactericidal efficacy.\n-   **Unchanged Ethambutol (EMB):** Ethambutol is primarily cleared by the kidneys and has a low hepatic metabolism fraction ($f_{\\text{hep,EMB}}=0.20$), making it minimally hepatotoxic. Its dose does not require adjustment for hepatic dysfunction. Maintaining its full dose is important to provide bacteriostatic coverage and, crucially, to help prevent the development of resistance to other drugs in the regimen, a role that is especially important given the omission of PZA.\n\nIn summary, the adjusted regimen prioritizes patient safety from severe hepatotoxicity. This safety comes at the cost of sacrificing the potent sterilizing activity of PZA and potentially reducing the efficacy of INH and RIF, which may require a longer treatment duration and careful clinical monitoring for response.",
            "answer": "$$\\boxed{954}$$"
        }
    ]
}